Q-Med, the Swedish biotech company, has launched an injectable gel called Macrolane, which is aimed at providing non-surgical solution to women who want to enlarge their breasts.

June 13, 2009, (Sawf News) - Q-Med, the Swedish biotech company, has launched an injectable gel called Macrolane, which is aimed at providing non-surgical solution to women who want to enlarge their breasts.

This product claims to offer women instant volume and lift which lasts for 12-18 months after which the substance disintegrates and is expelled by the body.

Macrolane consists of hyaluronic acid, a substance found naturally in skin and connective tissue. Q-Med uses its patented technology NASHA (non-animal) to manufacture Macrolane, which makes the product non-allergenic. Q-Med claims that the side effects are much lesser and the risk profile is much safer.

Macrolane treatment. Photo Credit: Macrolane.co.uk

Though it’s clearly mentioned on Q-Med’s official website that ‘Use of NASHA gel has been clinically proven and well documented in facial aesthetics for over 10 years’, its efficacy for breast enhancements is still up in the air.

Alice Hart Davis, one of the first women in UK to try Macrolane, feels that this breast enhancing injection under-delivers and does not seem to be backed up by the sort of studies that people might expect. While sharing her traumatic personal experience she reveals how she had missed to read the fine print which stated that ”Macrolane’s use for breast enhancement has not been established and that in small studies adverse reactions had included development of hardness of the breast, formation of palpable lumps and capsular contraction”.

Macrolane for breasts has been approved in the EU on the basis of a study into its use for correcting liposuction deformities, and a currently unfinished study on its use on breasts in 24 people. Neither examined long-term effects, so nothing can be said for sure about the safety of this product. Macrolane is still not approved by FDA in USA.

This expensive gel (it costs up to £3,000 for a treatment that should last 18 months with £1,000 for a boost) has been used by 2,000 women in its first year with a British trial still awaiting approval and a study on 75 patients underway in Sweden and France.

News Copyright © Sawf News. May not be reproduced without explicit written permission